as 07-26-2024 4:00pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 270.4M | IPO Year: | 2017 |
Target Price: | $5.57 | AVG Volume (30 days): | 1.1M |
Analyst Decision: | Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.13 | EPS Growth: | N/A |
52 Week Low/High: | $0.96 - $6.28 | Next Earning Date: | 08-06-2024 |
Revenue: | $38,298,000 | Revenue Growth: | 18.40% |
Revenue Growth (this year): | 9.86% | Revenue Growth (next year): | -19.46% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
MISRA TUSHAR | MRSN | SVP, Chief Manuf. Officer | Jan 13 '24 | Sell | $2.71 | 3,357 | $9,097.47 | 17,966 | SEC Form 4 |
Lowinger Timothy B | MRSN | SVP, Chief Sci.&Tech. Officer | Jan 13 '24 | Sell | $2.71 | 10,409 | $28,208.39 | 199,329 | SEC Form 4 |
Protopapas Anna | MRSN | Director | Jan 13 '24 | Sell | $2.71 | 29,399 | $79,671.29 | 125,153 | SEC Form 4 |
Mandelia Ashish | MRSN | VP, Chief Accounting Officer | Jan 13 '24 | Sell | $2.71 | 5,025 | $13,617.75 | 23,328 | SEC Form 4 |
Carvajal Alejandra | MRSN | SVP, Chief Legal Officer | Jan 13 '24 | Sell | $2.71 | 4,381 | $11,872.51 | 27,403 | SEC Form 4 |
Bala Mohan | MRSN | SVP, Chief Development Officer | Jan 13 '24 | Sell | $2.71 | 3,431 | $9,298.01 | 14,052 | SEC Form 4 |
DeSchuytner Brian | MRSN | SVP, COO & CFO | Jan 13 '24 | Sell | $2.71 | 9,327 | $25,276.17 | 54,511 | SEC Form 4 |
Bala Mohan | MRSN | SVP, Chief Development Officer | Oct 25 '23 | Sell | $1.13 | 1,912 | $2,160.56 | 8,733 | SEC Form 4 |
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
Yahoo Finance Video
2 months ago
GlobeNewswire
2 months ago
Reuters
2 months ago
USA TODAY
2 months ago
GlobeNewswire
2 months ago
Business Wire
2 months ago
Business Wire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.